An Open-Label study to assess the efficacy and potential for adrenal suppression following maximal use treatment with TA-102 topical formulations in subjects with Plaque Psoriasis.
Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of plaque psoriasis. Definite clinical diagnosis of stable plaque psoriasis for at least 6 months. Subjects must be in good health and free from any clinically significant disease, including but not limited to, conditions that may interfere with the evaluation of plaque psoriasis.
Exclusion Criteria:
Female Subjects who are pregnant, nursing or planning to become pregnant during study participation. History of allergy or sensitivity to retinoid, corticosteroids and/or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the Subject or the results of the study.
